CPEB4 plays an important role in
cancer progression. However, the clinicopathological significance of CPEB4 expression to
glioma and its expression levels in
glioma tissues and cell lines are unknown. The present study investigated the potential prognostic value of CPEB4 for human
glioma.Immunohistochemistry (IHC) was performed to examine the dynamics of CPEB4 expression in
glioma and nonneoplastic brain tissues, and the expression of CPEB4 in cell lines and freshly prepared tissue samples was measured using Western blotting and real-time PCR.CPEB4 was highly expressed at the
mRNA and
protein levels in 4
glioma cell lines and in 4 freshly prepared
glioma tissues. Immunohistochemical analysis demonstrated that CPEB4 expression in
glioma tissue was higher than that in corresponding nonneoplastic brain tissue (P < 0.01). This high expression level was further increased in high-grade
gliomas, and the CPEB4 expression level correlated with the WHO classification (r = 0.774, P < 0.01). Moreover, the overall survival of
glioma patients displaying high CPEB4
protein expression (P < 0.01) was clearly lower than that of those displaying low CPEB4 expression, and the high CPEB4 expression indicated a poorer survival in high-grade
glioma patients (P < 0.01).Our study suggests that CPEB4 is significantly expressed in human
glioma and that the upregulation of CPEB4
protein is significantly associated with advanced WHO grade. CPEB4 may serve as a highly sensitive prognostic
indicator for
glioma patients.